Important Notice from CHUGAI PHARMACEUTICAL

For Patient

Please view information about clinical trials sponsored by the Chugai Group here.

PICKUP CONTENTS

企業広告

Innovation Beyond Imagination - Chugai Brand Statement

Watch the video on our YouTube channel and discover how we’re bringing “Innovation Beyond Immagination” to life.

（別ウィンドウで開く）

Turning award-winning science into therapies

[Nature Portfolio － PARTNER CONTENT | Produced by Nature Custom Media] “A technology-driven approach is reaping results in immune research and novel antibody therapies.”

(Open in a new window)

Advanced and sustainable patient-centric healthcare

Learn about Chugai's core values, which prioritize each patient’s wellbeing as our highest consideration in conducting our business.

ABOUT

We get to the future ahead of the disease.

Share of therapeutic antibody sales in Japan*1Copyright © 2025 IQVIA. Calculated based on JPM 2024. Reprinted with permission. The scope of the market is defined by Chugai.

No.1

Breakthrough Therapy Designations*2A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.

9times

Countries approving Chugai products

More than110

Operating profit growth after starting the strategic alliance with Roche (2002-2025)

23.3times higher

Chugai is a research and development-oriented pharmaceutical company with unique technology and science as its strengths. In collaboration with Roche, we are committed to continuously generating innovation with the aim of continuously providing patients with innovative drugs and services.

For those who want to know about
Chugai’s characteristics and strengths
What kind of company is Chugai Pharmaceutical?
For those who want to know more about
Chugai
About Chugai

  • *1 Copyright © 2026 IQVIA. Calculated based on JPM 2025. Reprinted with permission. The scope of the market is defined by Chugai.

  • *2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.

The three key drivers driving Chugai's growth are RED*Research and Early Development Shift, DX, and open innovation.
We will shift our resources to discovery
research and early clinical development, which are the source of our value creation, apply digital technology to create innovative new drugs and increase efficiency in the value chain, and actively collaborate with external partners.

* Research and Early Development

The purpose of innovation, R&D efforts, and results

Innovation

SUSTAINABILITY

Putting sustainability at the heart of our business
Creating shared value with Society and developing together

We aim to lead solving social issues through our business activities, share the value created through these activities with our diverse stakeholders, and to grow together with society.

Chugai's Perspective on Social Issues and How to Solve Them

We aim to lead solving social issues through our business activities, share the value created through these activities with our diverse stakeholders, and to grow together with society.

Chugai's Perspective on Social Issues and How to Solve Them

The 6th Workshop on Multidisciplinary Team Care for Healthcare Professionals in Cambodia ～Co‐Creation Zoo: Artistic Approach to Team Building Workshop～

  • Advanced and sustainable patient-centric healthcare
  • Global Health
  • Social Contribution

Protection of the Global Environment

  • Social Contribution
  • Society
  • Global Environment

Supporting the Cervical Cancer Elimination Program in Marshall Islands and Fiji

  • Global Health

Support for improving access to health care in remote villages in Nepal

  • Global Health

Certified as a “Water Cycle ACTIVE Company” under the Water Cycle Corporate Registration and Certification Program of the Cabinet Secretariat

  • Global Environment

Chugai Life Science Park Yokohama Receives the MLIT Minister’s Award in the Business Activity Category at the 45th Green City Award

  • Global Environment

Development of a New Shipping Container to Significantly Reduce CO2 Emissions During the Shipping of Bio Drug Substances

  • Global Environment

Support for a remote ophthalmology screening project in Cambodia 2025

  • Advanced and sustainable patient-centric healthcare
  • Global Health
  • Social Contribution

View all Chugai activity reports

Activity Reports

Stories

Creating Continuous Innovation.
The Story of Our Challenges

  • #Patient-Centricity
  • #Science and Technology
  • #Digital Technology

Creating New Forms of Patient Contribution Through Real‑World Data: How the Drug Safety Division Is Leading the Way

Chugai Pharmaceutical is promoting the company-wide use of real-world data (RWD)*¹. In this article, we focus in particular on project members from the Dr

  • R&D
  • DX
  • Sustainable Healthcare
  • #Patient-Centricity
  • #Science and Technology
  • #Sustainability

Innovating Pharmaceutical Packaging to Protect Patients and the Planet: Chugai's Challenge to Implement Recycled Plastics and Biomass-Based Materials

Pharmaceutical packaging is far more than a simple container. It serves a vital mission: safeguarding drug quality, supporting improved usability for patients,

  • R&D
  • Sustainability
  • Sustainable Healthcare
  • Global Environment
  • #Patient-Centricity
  • #Science and Technology
  • #Co-Creation

"Creating Drugs That Benefit the World": A Century of Purpose and the Future Chugai Is Building

On March 10, 2025, Chugai Pharmaceutical celebrated its 100th anniversary. To commemorate this milestone, we held a Commemorative Ceremony in May 2025, welcomi

  • Innovation
  • Sustainable Healthcare
  • 100th Anniversary
  • #Patient-Centricity
  • #Digital Technology
  • #Co-Creation

Carrying Patient Voices Into the Future: Japan’s Bleeding Disorders Registry

Delivering optimal care even for rare diseases — driven by this commitment, patient advocacy groups, an academic society, and a pharmaceutical company jo

  • Disease Awareness
  • Sustainable Healthcare
  • #Science and Technology
  • #Open Innovation

“CHUGAI INNOVATION DAY 2025” Event Report

The business conference "CHUGAI INNOVATION DAY 2025" hosted by Chugai Pharmaceutical was held at Marunouchi Building Hall & Conference Square (Marunouchi,

  • Innovation
  • R&D
  • DX
  • Partnering
  • Event
  • 100th Anniversary
  • #Co-Creation

Passing the Baton of Passion: The "My Action Declaration" 100th Anniversary Project

On March 10, 2025, Chugai Pharmaceutical celebrated its 100th anniversary. As part of this historic milestone, the company launched "My Action Declaration," an

  • Innovation
  • #Business Models
  • #Science and Technology
  • #Digital Technology

Pharmaceutical Development Accelerated with Real-world data (RWD) - Taking on the Challenge of Developing Acute-phase Therapeutic Drugs in Collaboration with MeDiCU, Inc.

Chugai Pharmaceutical utilizes real-world data (RWD)* for increased efficiency and advancement in the clinical development of new drugs, verification of drug v

  • R&D
  • DX
  • External Experts
  • #Science and Technology
  • #Open Innovation

Creating and Expanding Regulatory T cells: The Possibility of Cellular Therapy Explored by a Joint Research Team from Chugai and the Immunology Frontier Research Center (IFReC), the University of Osaka

The immune system protects the body from harm. In this process, regulatory T cells act as regulators or brakes suppressing excessive immune responses. A recent

  • Innovation
  • R&D

Our employees want to bring happiness to our patients. Here are the thoughts of these employees and the stories of their challenges.

Read Chugai's culture

Stories

UPDATE

Latest Information

Notices What's new News

There are currently no announcements.

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.